Santaris, Silence Therapeutics, Oxford, Sigma, Alnylam

Jul 05, 2007

Premium

Santaris Receives Grant to Develop miRNA-Targeting Drug

Santaris Pharma said this week that it has received a €1.35 million ($1.8 million) grant from the Danish National Advanced Technology Foundation to develop SPC3649, a locked nucleic acid-based drug that targets the microRNA miR-122.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Testing, Testing for Mutations

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

Hide, Nessie, Hide

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

Even More Variety

The New York Times writes about the appearance of mosaicism in healthy people.

This Week in PNAS

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Featured White Papers

The Ultimate Guide to Mouse Clinical Trials

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

How to Perform Successful CRISPR Experiments

High Throughput RT-qPCR for Gene Expression Analysis

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Main menu